bioAffinity Technologies Inc

The company maintains a strong liquidity position with $6.45 million in cash and equivalents, representing 58.8% of total assets. Its debt-to-equity ratio of 0.11 indicates a conservative capital structure, with long-term debt accounting for just 7.5% of total liabilities. The current ratio of 2.6 suggests the company can cover short-term obligations twice over, though negative operating cash flow of -$9.33 million and free cash flow of -$14.47 million highlight ongoing cash burn. Profitability metrics are sharply negative, with a return on equity of -204.87% and return on assets of -136.03%. These figures fall well below the industry median for medical equipment firms, which typically report positive ROE and ROA in the 5-15% range. Gross margin of 31.4% is in line with industry norms, but operating margin of -171.7% and net margin of -242.0% indicate severe cost overruns. The company operates as a single-segment business with 100% revenue concentration in its diagnostic products division. Geographic exposure is not disclosed in the latest filings, but the company is incorporated in the United States and maintains operations in Canada. No material revenue concentration by geography is reported. Revenue of $6.16 million represents a 12.3% year-over-year decline from $6.99 million in the prior period. The company projects a 15-20% revenue contraction for the current fiscal year, driven by delayed regulatory approvals and supply chain bottlenecks. No material capital expenditures are planned for FY2025, with capex of -$60,570 in the most recent period. Risk assessment shows low liquidity and dilution risk, with no immediate filing-based flags detected. The company has 4.5 million shares outstanding with no difference between basic and diluted shares, indicating no near-term dilution pressure. However, the negative net income of -$14.91 million and operating loss of -$10.57 million raise concerns about long-term sustainability. Recent 10-K filings disclose ongoing clinical trials for new diagnostic assays and a pending FDA submission for a rapid SARS-CoV-2 test. The company also announced a partnership with a Canadian hospital network to expand its point-of-care testing capabilities. No material legal or regulatory issues were disclosed in the latest quarterly reports.